Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct;38(10):1777-1789.
doi: 10.1007/s00296-018-4040-2. Epub 2018 May 5.

Renal involvement in antiphospholipid syndrome

Affiliations
Review

Renal involvement in antiphospholipid syndrome

Francisco Vileimar Andrade de Azevedo et al. Rheumatol Int. 2018 Oct.

Abstract

This is a review of scientific publications on renal involvement in antiphospholipid syndrome (APS), with focus on clinical and histopathological findings and treatment. A search for English-language articles on renal involvement in APS covering the period 1980-2017 was conducted in Medline/PubMed and Scopus databases using the MeSH terms "antiphospholipid syndrome", "antiphospholipid antibodies", "glomerulonephritis" and "thrombotic microangiopathy" (TMA). APS nephropathy is primarily the result of thromboses in renal arteries or veins, intraparenchymatous arteries and glomerular capillaries. On histology, APS nephropathy is characterized by TMA, but chronic vaso-occlusive lesions are also commonly observed (fibrous intimal hyperplasia, focal cortical atrophy, fibrous occlusions of arteries). Anticardiolipin and lupus anticoagulant are the most prevalent antibodies in patients with APS nephropathy. The spectrum of renal manifestations includes renal vein thrombosis, renal artery thrombosis/stenosis, TMA, increased allograft vascular thrombosis and malignant hypertension. Anticoagulation is the standard treatment of thrombotic events. In systemic lupus erythematosus (SLE) patients with antiphospholipid antibodies (aPL), kidney failure due to SLE nephritis (immune-complex disease) should be clearly distinguished from kidney failure due to APS-related TMA. In such cases, renal biopsy is mandatory. SLE nephritis requires immunosuppressive therapy, whereas APS nephropathy is usually treated with anticoagulants. Recently, eculizumab and sirolimus have been proposed as a rescue therapy. Based on our review, APS nephropathy appears to be a distinct clinical condition. TMA is a characteristic histopathological finding in APS and is strongly associated with the presence of aPL. This has important therapeutic implications and allows distinguishing APS nephropathy from lupus nephritis.

Keywords: Antiphospholipid antibodies; Antiphospholipid syndrome; Thrombotic microangiopathy.

PubMed Disclaimer

References

    1. Rheumatology (Oxford). 2001 Aug;40(8):863-7 - PubMed
    1. JAMA. 2006 Mar 1;295(9):1050-7 - PubMed
    1. Chest. 2008 Jun;133(6 Suppl):844S-886S - PubMed
    1. Arthritis Res Ther. 2014;16(2):209 - PubMed
    1. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15542-6 - PubMed

MeSH terms

Substances

LinkOut - more resources